good 11am from India.
and a wonder full
Pichikara
War ein gefährliches Spiel bis heute. Nach den news von heute hat die Aktie ein Kursziel von +- 18.75$ Das offene Gap macht diese Aktie im Moment aber unberechenbar.
PS: OXBT hatte ein hoch von 11.40$. Genau 1.00.- Dollar über meinem Kursziel.
Diese Tatsache ist mit dem Zeitfaktor zu relativieren, darum war sie auch nicht lange da oben. 
[Blocked Image: http://www.finviz.com/chart.ashx?t=VNDA&ty=c&ta=1&p=d&s=l]
1. bin ich ein Kandidat? Dieser bist du.
2. b00n hat ideen, aber auch keine.
3. Machs doch selber.
4. Let the music play.
See you tomorrow over 10.00$
Die Erklärung folgt.
2brix hat am 05.11.2013 - 20:38 folgendes geschrieben:
Quote2brix hat am 05.11.2013 - 17:17 folgendes geschrieben:
Meistens kostet das doch und wird eher negativ gesehen bezüglich Kosten usw. Siehe bsp swissquote
Interessant das du swissquote in diesem Zusammenhang erwähnst.
Nedoli hat am 05.11.2013 - 18:44 folgendes geschrieben:
QuoteLeck du mer am tschope.... smiley
8.22$
Musste wieder an Board
keine ahnung... top oder flop
Hoi Nedoli. ich sehe den Schlusspfiff bei 10.40$. Nächster grosser Widerstand aus 2012. Evolva style hier mit OXBT.
t Schwiiz ruumt im Amiland uf.
ouwee.
Aurum hat am 24.10.2013 - 21:25 folgendes geschrieben:
QuoteDNDN hat für USA auch noch keinen Partner, was aber die Chance auf einen EU Partner nicht schmälert.
Oder einen Partner in der SU. Hey, Chancen sind da. 
jup, vorallem mit Event und Preis history. thanks. ARQL is auch auf meiner liste.
Quote
Its moving.
Red Bull hat am 06.09.2013 - 21:51 folgendes geschrieben:
Quotehttp://www.nzz.ch/aktuell/wirtschaft/wirtschaftsnachrichten/die-schweize...
Ich hoffe auf schlechte Zahlen
wette gilt.
LONDON — The first consumer magazine from Net-a-porter’s new publishing division will be called Porter.
According to the company, Porter will be “for and about women with great style,” bringing together editors, writers, stylists and photographers who will be led by editor in chief Lucy Yeomans, formerly of Harper’s Bazaar U.K.
“The name Porter has a strength, wit, elegance and intelligence that speaks perfectly to the modern female audience and yet it has a timelessness to it that feels as if it could have existed for decades,” said Yeomans, describing the Porter woman as “strong, stylish, intelligent and adventurous.”
She added that her role, as editor, is to “seduce, satisfy and serve” her readers, adding that “the power, expertise and reach of Net-a-porter will also offer her the experience and service that she has come to expect, turning inspiration from the page into accessibility within seconds.”
It will be published six times a year, and have a global distribution at newsstands and via subscription. Its 300 pages will be transactional via mobile phone and via an app, built in-house. The cover price has not been revealed, but the publication will launch in February 2014. Content is being produced by a dedicated team, with contributions from Net-a-porter’s free, weekly online magazine called The Edit, the sister title of Porter.
Tess MacLeod-Smith, vice president of publishing and media at Net-a-porter, said, “The magazine will have the power to reach the most affluent and proactive fashion consumer base in the world via Net-a-porter’s global audience of over 6 million monthly unique visitors and customers.”
The publication was originally slated to launch this fall but was postponed in June until early 2014 in order to introduce a mobile brand platform, which was originally set to launch in 2014. However, the company, which is owned by Compagnie Financière Richemont SA, brought the launch date forward because it wanted to be first to market with the new app, which will be introduced in the near future.
HONG KONG, China — Most people are shocked to learn that the executive chairman of Shanghai Tang, the Hong Kong-based luxury lifestyle brand, is a Frenchman by the name of Raphael le Masne de Chermont. While the brand is still closely associated with its original founder Sir David Tang, since 2002, le Masne de Chermont, while not Chinese by blood, has played a pivotal role in establishing Shanghai Tang as China’s first internationally recognised luxury label.
Shanghai Tang began with a small fashion boutique in the Pedder Building in Hong Kong’s Central district. The brainchild of entrepreneur David Tang, it offered custom and ready-made garments inspired by Chinese fashion in the 1920s, including silk scarves, qi paos and, of course, their famous velvet jackets lined with colourful silk. By the late 1990s, the brand was a favourite with the city’s wealthy Western expatriates and elite Brits like Kate Moss.
In 1998, Swiss luxury goods conglomerate Compagnie Financière Richemont SA took a controlling share in the company. Labelling itself the “global curator of modern Chinese aesthetics,” Shanghai Tang expanded their offering to include accessories and homewares, while opening stores around the world. By 2005, global sales had grown 43 percent, according to market sources. And by 2008, Richemont completed their acquisition of the company.
It’s no secret that Shanghai Tang has dedicated the past decade to courting the Chinese market. Of its 45 stores, 30 are in Greater China, including its latest flagship, Cathay Mansion, in Shanghai, the city that inspired the brand’s birth. To celebrate the store’s official opening last week, the brand hosted a glittering event complete with a catwalk show staged by its new designer, Joseph Li, a graduate of London’s Central Saint Martin’s.
Now, efforts are underway for expanding the brand in the West. Earlier this year Shanghai Tang entered into a 12-year worldwide licensing deal with Inter Parfums USA to create, produce and distribute perfumes and related products, with plans to launch its first fragrance in Spring 2014.
BoF spoke with Raphael le Masne de Chermont about Shanghai Tang’s customer base, re-energising the company’s ready-to-wear, global expansion plans, and whether Chinese consumers will ever truly embrace a luxury brand founded in the East.
QuoteBy Vanda Pharmaceuticals Inc.
WASHINGTON, AUG. 7, 2013 — /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)(NASDAQ: VNDA) today announced the sale of 4,680,000 shares of its common stock in an underwritten public offering at a price to the public of $11.14 per share. The net offering proceeds to Vanda from the sale of the shares are expected to be approximately $48.3 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriters' over-allotment option.
FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
The
"We are extremely pleased that the
The
About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. Non-24 affects a majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S. Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to entrain the master body clock in the brain with the 24-hour day-night cycle. Most people have a master body clock that naturally runs longer than 24-hours and light is the primary environmental cue that resets it to 24 hours each day. Individuals with Non-24 have a master body clock that is not reset, and continually delays, resulting in prolonged periods of misalignment between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion. As a result of this misalignment, Non-24 is associated with significant disruption of the sleep-wake cycle and impairments in social and occupational functioning, and marked subjective distress. Currently there is no approved treatment for Non-24. For more information on Non-24, please visit www.Non-24.com.
http://phx.corporate-ir.net/ph…cle&ID=1842208&highlight=
[Blocked Image: http://www.finviz.com/chart.ashx?t=VNDA&ty=c&ta=1&p=d&s=l]
00ps hat am 22.05.2013 - 15:10 folgendes geschrieben:
QuoteJemand in Intelgenx Technologies Corp investiert? Scheinbar sollten sie nächstens NDA Akzeptanz von der FDA bekommen...
IGXT Chart:
Diese Firma hab ich mir mal auf watch genommen.
Sie erwarten eine definitive FDA Zulassung bis Ende Q3.
Ich sehe hier Chancen bis auf 9.00$ per Share nach oben und 4.50$ nach unten.
Abgesehen von den jetzigen Financials und der hohen Shortposi gefällt mir die Aktie. Have fun.
[Blocked Image: http://img854.imageshack.us/img854/1603/unbenanntoml.png]
[Blocked Image: http://finviz.com/chart.ashx?t=SUPN&ty=c&ta=1&p=d&s=l]
[Blocked Image: http://finviz.com/chart.ashx?t=JAZZ&ty=c&ta=1&p=d&s=l]
Ein positives FDA Panel am 02.05.13 würde für Auftrieb sorgen. Bin aber eher zurückhaltend.
2.50$ könnten spekulativ drinliegen.
DELCATH ANNOUNCES ODAC MEETING REVIEW DATE FOR ITS PROPRIETARY DRUG/DEVICE COMBINATION PRODUCT DELCATH HEPATIC DELIVERY SYSTEM
Meeting to be Held May 2, 2013
NEW YORK, Feb. 27, 2013 -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the Company's pending New Drug Application (NDA) for a drug/device combination product with the proposed trade name Melblez KitTM (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System. The ODAC meeting will be convened Thursday, May 2, 2013, to review the NDA with a proposed indication for the treatment of patients with unresectable ocular melanoma that is metastatic to the liver.
ODAC panels advise the U.S. Food and Drug Administration on the safety and efficacy of proposed new cancer therapies. The FDA is not legally bound to follow the advice of its advisory committees regarding new drug applications. Delcath's NDA was accepted by the FDA for substantive review on October 15, 2012, and was assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 15, 2013.
Eamonn P. Hobbs, President & CEO of Delcath Systems, said, "Our team is actively preparing for the ODAC meeting and we look forward to presenting our data for the safety and efficacy of Delcath's system for the treatment of patients with unresectable ocular melanoma metastatic to the liver to the ODAC panel."
The FDA will publish materials, including webcast information, pertaining to the meeting at http://www.fda.gov/AdvisoryCommittees/WhatsNew/default.htm.
Changes to the Advisory Committee meetings calendars may also be found on the FDA website at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
[Blocked Image: http://finviz.com/chart.ashx?t=DCTH&ty=c&ta=1&p=d&s=l]
